The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 58
- Registration Number
- NCT03673215
- Locations
- 🇨🇳
302 Military Hospital of China, Beijing, Beijing, China
A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 40
- Registration Number
- NCT03388515
- Locations
- 🇨🇳
The First Affilicated Hospital Zhejiang University, Hangzhou, Zhejiang, China
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 207
- Registration Number
- NCT02947438
- Locations
- 🇷🇺
St-Peterburg State healthcare institution "Municipal hospital of "Elizabethan Hospital, Saint Petersburg, Russian Federation
🇷🇺State budgetary institution "St-Petersburg' scientific-research institution of emergency n.a Dzanelidze)", Saint Petersburg, Russian Federation
🇷🇺Federal State Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation, Samara, Russian Federation
Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 16
- Registration Number
- NCT02522975
- Locations
- 🇹🇭
Rajavithi hospital, Bangkok, Thailand
🇹🇭Siriraj Hospital, Bangkok, Thailand
🇹🇭Chulalongkorn King Memorial hospital, Bangkok, Thailand
A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 72
- Registration Number
- NCT02460393
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
- Conditions
- Interventions
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 40
- Registration Number
- NCT02356419
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
- Conditions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 120
- Registration Number
- NCT02344979
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China